Evidence map›Paper›PMID 31052360›Full record

ArticlePharmaceutics2019

A Functional Wound Dressing as a Potential Treatment for Cutaneous Leishmaniasis.

Francisco Alexandrino-Junior, Kattya Gyselle de Holanda E Silva, Marjorie Caroline Liberato Cavalcanti Freire, Viviane de Oliveira Freitas Lione, Elisama Azevedo Cardoso, Henrique Rodrigues Marcelino, Julieta Genre, Anselmo Gomes de Oliveira, Eryvaldo Sócrates Tabosa do Egito

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Rational Design of Immunomodulatory Hydrogels for Chronic Wound Healing.Advanced materials (Deerfield Beach, Fla.) · 2021
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Francisco Alexandrino-JuniorPrograma de Pós-Graduação em Nanotecnologia Farmacêutica (PPgNANOFARMA), Universidade Federal do Rio Grande do Norte (UFRN), Nata/RN 59012-570, Brazil. alexandrino_jr@yahoo.com.br.ORCID 0000-0002-1173-9164
Kattya Gyselle de Holanda E SilvaFaculdade de Farmácia, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro/RJ 21941-902, Brazil. holanda.gyselle@gmail.com.
Marjorie Caroline Liberato Cavalcanti FreireInstituto de Física de São Carlos, Universidade de São Paulo (USP), São Carlos/SP 13563-120, Brazil. marjorie_freire_@hotmail.com.ORCID 0000-0001-7734-5144
Viviane de Oliveira Freitas LioneFaculdade de Farmácia, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro/RJ 21941-902, Brazil. vivianelione@gmail.com.
Elisama Azevedo CardosoFaculdade de Farmácia, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro/RJ 21941-902, Brazil. elisamaazevedo@gmail.com.
Henrique Rodrigues MarcelinoDepartamento do Medicamento, Universidade Federal da Bahia (UFBA), Salvador/BA 40170-115, Brazil. henrique.rmarcelino@gmail.com.ORCID 0000-0002-3625-7786
Julieta GenreFaculdade de Farmácia, Universidade Federal do Rio Grande do Norte (UFRN), Nata/RN 59012-570, Brazil. jgenre@gmail.com.
Anselmo Gomes de OliveiraDepartamento de Fármacos e Medicamentos, Universidade Estadual Paulista (UNESP), Araraquara/SP 14800-903, Brazil. ans_gomes@yahoo.com.br.
Eryvaldo Sócrates Tabosa do EgitoPrograma de Pós-Graduação em Nanotecnologia Farmacêutica (PPgNANOFARMA), Universidade Federal do Rio Grande do Norte (UFRN), Nata/RN 59012-570, Brazil. socratesegito@gmail.com.ORCID 0000-0002-2180-3991
Universidade Federal do Rio de Janeiro · BRUniversidade Federal do Rio Grande do Norte · BRUniversidade de São Paulo · BRUniversidade Estadual Paulista (Unesp) · BRUniversidade Federal da Bahia · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico FellowshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior 001
6 · The paper itself

Abstract

Cutaneous leishmaniasis (CL) is a parasitic disease characterized by progressive skin sores. Currently, treatments for CL are limited to parenteral administration of the drug, which presents severe adverse effects and low cure rates. Therefore, this study aimed to develop poly(vinyl-alcohol) (PVA) hydrogels containing Amphotericin B (AmB) intended for topical treatment of CL. Hydrogels were evaluated in vitro for their potential to eliminate promastigote forms of

Indexed as

Amphotericin Bcontrolled releasecutaneous leishmaniasishydrogelwound dressing

Identifiers

PMID31052360
PMCPMC6571773
OpenAlexW2942951059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.